Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome

Phase 3 BOSTON clinical studies will evaluate Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), the first potential therapy for Bronchiolitis Obliterans Syndrome (BOS) BOS is a devastating lung disease with high mortality affecting over 30,... Biopharmaceuticals Breath Therapeutics, Bronchiolitis Obliterans Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news